Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Net Margin (2021 - 2025)

Historic Net Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 291231.82%.

  • Allogene Therapeutics' Net Margin rose 322115200.0% to 291231.82% in Q1 2024 from the same period last year, while for Dec 2024 it was 1151031.82%, marking a year-over-year decrease of 8253160300.0%. This contributed to the annual value of 1170863.64% for FY2024, which is 8263741600.0% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Net Margin of 291231.82% as of Q1 2024, which was up 322115200.0% from 375447.62% recorded in Q4 2023.
  • Over the past 5 years, Allogene Therapeutics' Net Margin peaked at 2.5% during Q4 2021, and registered a low of 375447.62% during Q4 2023.
  • For the 4-year period, Allogene Therapeutics' Net Margin averaged around 223087.67%, with its median value being 258140.91% (2023).
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2022, then surged by 437442800bps in 2023.
  • Over the past 4 years, Allogene Therapeutics' Net Margin (Quarter) stood at 2.5% in 2021, then crashed by -14392819bps to 360146.15% in 2022, then decreased by -4bps to 375447.62% in 2023, then increased by 22bps to 291231.82% in 2024.
  • Its last three reported values are 291231.82% in Q1 2024, 375447.62% for Q4 2023, and 258140.91% during Q3 2023.